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Abstract 
4-Bromomethylcoumarins (1a-f) were reacted with 8-
hydroxyquinoline to yield quinolinoxymethylcoumarins 
(2a-f). The structure of all the synthesized compounds 
were confirmed by spectral studies and screened for their 
anticancer activities against Dalton’s Ascitic lymphoma 
(DAL) and Ehrlich Ascites Carcinoma (EAC) cell lines.  
Out of these, compound (2b) (R = 6-OMe) was found to 
be the most potent cytotoxic compound against DAL and 
EAC cell lines.             
Keywords:  4-Bromomethylcoumarins, Coumarins, Quinoline, 
Cytotoxic activity. 
1. Introduction 
A large number of naturally occurring compounds possessed 
heterocyclic rings as an important part of their structure.  Such 
compounds including indole, quinoline, benzimidazole, coumarins 
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and imidazopyridines are widely used as medicines.  Among them, 
quinoline and its derivatives exhibited remarkable activities such as 
antimalarial [1], antiproliferative [2], photosynthesis-inhibiting [3], 
proteasome inhibitors [4] and antioxidative activities [5]. They also 
act as antifungal [6], antibacterial [7], antiprotozoic drugs as well as 
exhibit antineoplastics [8] and antischistosomal activity [9]. 
Compounds containing coumarin rings have remarkable medicinal 
value due to their potential anticancer [10], antimicrobial [11] and 
antiulcerogenic effect [12] properties.  They also act as fluorescent 
probes [13].  In addition, 4-heteroaryloxymethylcoumarins are 
reported to exhibit significant biological activities such as 
antibacterial [14], antifungal [15], antimicrobial [16], antidiuretic 
[17] and anti-inflammatory activity [18]. 
On the basis of these literature studies, we set out to synthesize a 
new series of biologically active compounds containing both of 
these two important pharmacophores.  This study presents the 
synthesis, characterization and in vitro cytotoxic activities of these 
new quinolinoxymethylcoumarins            
1.1 Chemistry 
4-Bromomethylcoumarins [19] (1a-f) were synthesized by the 
Pechmann cyclisation of phenols with 4-bromoethylacetoacetate 
[20]. 6-Methyl-4-bromomethylcoumarin reacted with 8-
hydroxyquinoline in the presence of anhydrous K2CO3 to give 6-
methyl-4-(quinolin-8-yloxymethyl)-chromone-2-one [21]. We have 
extended the same method to other substituent of 4-



















R = a; 7-CH3, b; 6-OMe, c; 5,6-Benzo, d; 6-Cl, e; 6-Br, f; 6-F. 
Scheme 1. 
2. Results and Discussion 
2.1 In vitro anticancer screening 
The newly synthesized compounds were evaluated for their in vitro 
cytotoxic activity against Dalton’s Lymphoma Ascites (DAL) and 
Ehrlich Ascites Carcinoma (EAC) Cells using Dhamija method [22].  
5-Fluorouracil which is one of the most effective anticancer agents 
was used as the reference drug in this study. 
The relationship between surviving fraction and drug 
concentration was plotted to obtain the survival curve of Dalton’s 
Lymphoma Ascites (DAL) and Ehrlich Ascites Carcinoma (EAC) 
cells. The response parameter calculated was the IC50 value, which 
corresponds to the concentration required for 50% inhibition of cell 
viability.  The IC50 of the synthesized compounds compared to the 
reference drug are shown in Table 1 and the results are represented 
graphically in Figure 1.  
The investigation of in vitro cell cytotoxicity (Table 1) against DAL 
cell revealed that the most of the tested compounds exhibited good 
activity.  The Compound (2b) (R = 6-OCH3)   was found to be the 
most potent against DAL cell with IC50 value of 50.76 µg/mL.  The 
compound (2e) (R= 6-Br) was found to be highly active against 
DAL cell with IC50 value of 65.87 µg/mL.  The compounds (2a) (R= 
7-CH3), (2c) (R= 5,6-Benzo) and (2d) (R= 6-Cl) showed moderate 
activity against DAL cell with IC50 between 78.01 and 84.54 µg/mL.  
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The compound (2f) (R= 6-F) showed poor activity against DAL cell 
with IC50 104.25 µg/mL. 
The investigation of in vitro cell cytotoxicity (Table-1) against EAC 
cell revealed that the most of the tested compounds exhibited good 
activity.  The Compound (2b) (R = 6-OCH3) was the most potent 
compound in this screening against EAC cell with IC50 value of 
41.25 µg/mL. The compounds (2d) (R = 6-Cl) and (2f) (R = 6-F) 
were found to be highly active against EAC cell with IC50 value 
between 69.96 and 56.41 µg/mL.  The compounds (2a) (R = 7-CH3), 
(2c) (R = 5,6-Benzo)  and  (2e) (R = 6-Br) showed poor activity 










Table 1:  Result of in vitro cytotoxic activity of the synthesized compounds against DAL & 







Figure 1:  IC50 μg/mL of the synthesized compounds and 5-Flourouracil against DAL & EAC cells.       
Compound R DAL  IC50  EAC  IC50 
2a 7-CH3 84.54 110.34 
2b 6-OCH3 50.76 41.25 
2c 5,6-Benzo 78.01 104.67 
2d 6-Cl 81.25 69.96 
2e 6-Br 65.87 115.23 
2f 6-F 104.25 56.41 
5-Flurouracil 41.60 41.60 
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3. Experimental section  
3.1 General 
The melting points were determined by open capillary method 
using electric melting point apparatus and are uncorrected. The IR 
spectra (KBr disc) were recorded on a Shimadzu-8400S FT-IR 
Spectrophotometer.   1H NMR and 13C NMR were recorded on 
Bruker 400 MHz spectrometer by using CDCl3 as a solvent and 
TMS as an internal standard. The chemical shifts are expressed in δ 
ppm. The purity of the compound was checked by TLC. 
3.2. General procedure for the synthesis of 4-(quinolin-8-
yloxymethyl)-chromone-2-one (2a-f). 
8-Hydroxyquinoline (0.493g, 3.4 mmol) and anhydrous K2CO3 
(1.38g, 10 mmol) were stirred in 25 ml of dry acetone for 30 min.  
One of the 4-bromomethylcoumarins 1(a-f) (3.4 mmol) was added 
and stirring was continued for 24 h.  The reaction mixture was 
concentrated to one fourth volume and poured on to crushed ice.  
The solid separated was filtered and washed with 10 ml of 5% HCl. 
Then, it was washed with 50 ml of cold water.  The crude product 
was dried and recrystallised from ethanol.      
7-Methyl-4-(quinolin-8-yloxymethyl)-chromen-2-one. (2a) 
Yield 95%; colorless solid; m.p. 227 - 230 0C; IR (KBr, cm-1) 1725 cm-1 
(lactone C=O); 1H NMR (400 MHz, CDCl3): δ 2.52 (s, 3H, 7-CH3), 
5.64 (s, 2H, OCH2), 6.71(s, 1H, C3-H), 7.0 - 8.99 (m, 9H, Ar-H):  
13C NMR (400 MHz, CDCl3): δ 21.26, 67.20, 110.94, 114.12, 117.41, 
117.61, 121.79, 122.43, 123.79, 126.91, 130.17, 133.47, 134.65, 136.69, 
140.58, 149.99, 150.10, 152.33, 153.73, 161.17. 
6-Methoxy-4-(quinolin-8-yloxymethyl)-chromen-2-one.  (2b) 
Yield 90%; yellow solid; m.p. 155 - 160 0C; IR (KBr, cm-1) 1735 cm-1 
(lactone C=O); 1H NMR (400 MHz, CDCl3): δ 3.81 (s, 3H, OCH3), 
5.67 (s, 2H, OCH2), 6.75 (s, 1H, C3-H), 7.0 – 8.10 (m, 9H, Ar-H). 
1-(Quinolin-8-yloxymethyl)-benzo(f)chromen-3-one .(2c) 
Yield 85%; yellow solid; m.p. 185 - 188 °C; IR (KBr, cm-1) 1720 cm-1 
(lactone C=O); 1H NMR (400 MHz, CDCl3): δ 6.0 (s, 2H, OCH2), 6.96 
- 9.0 (m, C3-H & 12H, Ar-H). 




Yield 70%; colorless solid; m.p. 225 - 227 °C; IR (KBr, cm-1) 1725 cm-1 
(lactone C=O); 1H NMR (400 MHz, CDCl3): δ 5.55 (s, 2H, OCH2), 
6.80 (s, 1H, C3-H), 7.10 - 9.01 (m, 9H, Ar-H). 
6-Bromo-4-(quinolin-8-yloxymethyl)-chromen-2-one.  (2e) 
Yield 73%; brown solid; m.p. 202 – 207 0C; IR (KBr, cm-1) 1721 cm-1 
(lactone C=O); 1H NMR (400 MHz, CDCl3): δ 5.65 (s, 2H, OCH2), 
6.79 (s, 1H, C3-H), 7.10 - 9.0 (m, 9H, Ar-H). 
6-Fluoro-4-(quinolin-8-yloxymethyl)-chromen-2-one. (2f) 
Yield 40%; colorless solid; m.p. 229 - 232 0C; IR (KBr, cm-1) 1722 cm-1 
(lactone C=O);   1H NMR (400 MHz, CDCl3): δ 5.57 (s, 2H, OCH2), 
6.80 (s, 1H, C3-H), 7.09 - 9.0 (m, 9H, Ar-H). 
4. Conclusion 
The methoxy substitution at 6-position of coumarin moiety was 
found to enhance the in vitro cytotoxicity against both DAL and 
EAC cell lines. 
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